Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties

Lancet Respir Med. 2020 Dec;8(12):1170-1172. doi: 10.1016/S2213-2600(20)30503-8. Epub 2020 Oct 29.

Authors

Michael A Matthay¹, B Taylor Thompson²

Affiliations

¹ Cardiovascular Research Institute, Departments of Medicine and Anesthesia, University of California, San Francisco, CA 94143, USA. Electronic address: michael.matthay@ucsf.edu.
² Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

No abstract available

MeSH terms

COVID-19 Drug Treatment*
Dexamethasone / administration & dosage*
Dexamethasone / adverse effects
Glucocorticoids / administration & dosage*
Glucocorticoids / adverse effects
Humans
Pandemics
Pragmatic Clinical Trials as Topic
SARS-CoV-2

Substances

Glucocorticoids
Dexamethasone